Recent

% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • It is interesting to note from the ReNeuron official release that after 2 years the scores continued to improve, which is a major positive. Though, I will leave that to the experts. I'm sure the 2015 European Stroke Organization Conference (ESOC), taking place in Glasgow, April 19th, will be listening closely to ReNeuron.

    Excerpt from article:

    "Improvements in neurological status and limb function compared to pre-treatment baseline performance were observed within three months of treatment and maintained throughout long term follow-up. Improvements in the National Institutes of Health Stroke Scale (NIHSS) were seen in all dose groups. The NIHSS is a measure used to objectively quantify the impairment caused by a stroke."

    "For all subjects, the median baseline score was 7. This improved to 5 at 3 months and was sustained at 2 years follow up with a median score of 5 (p=0.002).
    Other measures of neuromuscular disability were supportive of the NIHSS improvement. Mean Ashworth Scale scores, a measure of limb spasticity, were 18.1 and 9.7 (affected upper and lower limb, respectively) at baseline, which improved to 15.7 and 7.8 at 3 months and 16.1 and 6.5 at 2 years. Improvements in scores on the Barthel Index (a measure of activities of daily living) were also
    consistent with the neuromuscular score changes with a median value of 12 at baseline, 14 at 3 months and 14 at 2 years."

  • Reply to

    An interesting silence

    by editroid2 Apr 14, 2015 11:54 PM

    Sorry about the typos. Correction:

    Not may, it will portend good news for China; Neuralstem and ReNeuron use the same technology. The original Neuralstem press release from the settlement with ReNeuron never detailed the amount of royalties and milestone payments that Neuralstem may potentially receive from ReNeuron.

    Neuralstem, ReNeuron and Stem Cells Inc all use the same stem cell technology. Of the three, ReNeuron has the best chance at Breakthrough Designation. However, this ReNeuron news should be huge for all three.

  • http://www.reneuron.com/images/stories/RNS%20notifications/ReNeuron%20-%20PISCES%20I%20data%20April%202015%20final.pdf

  • Reply to

    An interesting silence

    by editroid2 Apr 14, 2015 11:54 PM

    dogsscrewbrokerss broke that news yesterday. The post was deleted. Not may, it will portend good news for China; Neuralstem and ReNeuron use the same technology. The original Neuralstem press release from the settlement with ReNeuron never detailed the amount of royalties and milestone payments that Neurasltem may potentially receive from ReNeuron.

    Neuralstem, ReNeuorn and Stem Cells Inca ll use the same stem cell technolgoy. Of the three, ReNeuron has the best chance at Breakthrough Designation. However, this ReNeuron news should be huge for all three.

  • See the video on: "Differentiation of a Human Neural Stem Cell Line on Three Dimensional Cultures, Analysis of MicroRNA and Putative Target Genes"

    http://www.jove.com/video/52410/differentiation-human-neural-stem-cell-line-on-three-dimensional

  • It will be interesting to see the dollar amount of royalties that Neuralstem will receive from ReNeuron; based on the ReNeuron milestones and potential stem cell treatment approval for stroke. ReNeuron has progressed significantly.

    Remember this...

    "ReNeuron has agreed to immediately compensate Neuralstem, as well as to make future milestone and royalty payments to Neuralstem based on ReNeuron's development of certain products at issue in the case."

    See more at: http://investor.neuralstem.com/2011-01-28-Neuralstem-Inc-Settles-Litigation-Against-ReNeuron-Ltd#sthash.Td1CNjrD.dpuf

  • proactiveinvestors: By John Harrington April 17 2015, 3:06pm

    "ReNeuron heartened by stroke trial data"

    Improvements in neurological status and limb function compared to pre-treatment baseline performance were observed within three months of treatment and maintained throughout long term follow-up, ReNeuron said.
    Improvements in the National Institutes of Health Stroke Scale (NIHSS) - a measure used to objectively quantify the impairment caused by a stroke - were seen in all dose groups.

    For all subjects, the median baseline score was seven; this improved to five at three months and was sustained at two years follow- up with a median score of five.

    Other measures of neuromuscular disability were supportive of the NIHSS improvement.

    ReNeuron is currently conducting a UK multi-site Phase II clinical trial (PISCES II) to examine the efficacy of its CTX stem cell treatment in patients disabled by an ischaemic stroke. As a result of observed good safety profile of the treatment, the highest cell dose from the PISCES study is being used in the ongoing Phase II study.

    As with the PISCES study, the Phase II clinical trial involves a single, one-off injection of CTX cells into the brain. Subject to patient recruitment, initial data from this study are expected around the end of this year, ReNeuron told investors.

    Meanwhile, the long term follow-up data out to at least 24 months in all patients treated in the PISCES Phase I study are being presented by the clinical team from Glasgow's Southern General Hospital on 19th April in a platform presentation at the 2015 European Stroke Organisation Conference (ESOC), taking place in Glasgow.

  • http://www.reuters.com/article/2015/04/17/us-health-stemcells-reneuron-group-idUSKBN0N81CC20150417

  • Hey Dogsscrewbrokerss, they deleted your post. Thanks for the update on ReNeuron and the positive data on stroke!

    Fri Apr 17, 2015 8:50am EDT

    "ReNeuron stem cell therapy shows long-term promise for stroke"

    I(Reuters) - A pioneering stem cell treatment for patients disabled by stroke has continued to show long-term promise in a clinical trial, the British biotech company behind the project said on Friday.

    News that two-year follow-up data from a small Phase I study showed improvements in limb function with no worrying safety issues lifted shares in ReNeuron 10 percent by 0830 EDT.

    The clinical results were presented at the European Stroke Organisation Conference in Glasgow.

    The company said there had been no cell-related or immunological adverse events in any of the 11 patients treated. The only problems seen were related only to the implantation procedure or the patient's underlying medical condition.

    Improvements in neurological status and limb function were observed within three months of treatment and maintained throughout long-term follow-up.

    The procedure involves injecting ReNeuron's neural stem cells into patients' brains to repair areas damaged by stroke, thereby improving both mental and physical function.

    The Phase I trial is designed primarily to test whether the experimental treatment is safe.

  • Reply to

    An interesting silence

    by editroid2 Apr 14, 2015 11:54 PM

    Ehhhhh I don't know. Look what happened to ATHX!!!!

  • Reply to

    An interesting silence

    by editroid2 Apr 14, 2015 11:54 PM

    Nice catch. Since ReNeuron leases their technology from CUR, this may well portend good news from CUR's own PhaseI/II ongoing trial in China.

  • Reply to

    An interesting silence

    by editroid2 Apr 14, 2015 11:54 PM

    Possible good news coming out of China on stroke ??

    Related recent news from Europe Conference on stroke......

    Health | Fri Apr 17, 2015 8:50am EDT Related: SCIENCE, HEALTH
    ReNeuron stem cell therapy shows long-term promise for stroke
    LONDON
    (Reuters) - A pioneering stem cell treatment for patients disabled by stroke has continued to show long-term promise in a clinical trial, the British biotech company behind the project said on Friday.

    News that two-year follow-up data from a small Phase I study showed improvements in limb function with no worrying safety issues lifted shares in ReNeuron 10 percent by 0830 EDT.

    The clinical results were presented at the European Stroke Organisation Conference in Glasgow.

    The company said there had been no cell-related or immunological adverse events in any of the 11 patients treated. The only problems seen were related only to the implantation procedure or the patient's underlying medical condition.

    Improvements in neurological status and limb function were observed within three months of treatment and maintained throughout long-term follow-up.

    The procedure involves injecting ReNeuron's neural stem cells into patients' brains to repair areas damaged by stroke, thereby improving both mental and physical function.

    The Phase I trial is designed primarily to test whether the experimental treatment is safe.

  • From AP article: "He had pledged $100 million to the University of Michigan's A. Alfred Taubman Medical Research Institute and its stem-cell research by 2011. He also financed public-policy programs at Harvard, Brown University and the University of Michigan, which received several large donations.

    He donated millions and spoke passionately in support of the 2008 ballot initiative in Michigan that eased restrictions on embryonic stem-cell research and enabled his namesake institute to conduct major research for diseases — including amyotrophic lateral sclerosis, or Lou Gehrig's disease, which claimed the life of his good friend, New York Sen. Jacob Javits, in 1986."

  • Reply to

    Maxim

    by fasttimesgrad Apr 15, 2015 3:05 PM

    NVIV has been doing well. Scaffold+stemcells sounds like a 1-2 punch to me.
    Have a great day

  • 200k won't cover STEM's lab cleanup costs.

    Sentiment: Buy

  • Check yahoo earnings estimates now for your facts?

  • Link please

  • This is close to the dumbest post I have ever read. This probably goes head t ohead from one I read on SA on some plastic ducks and a comparison to clinical trials.

    Good job keep it up. You are definitely top five in my list.

  • STEM is facing delisting LOLOLOLOLOLOLOLOLOLOL

  • Stem revenue estimates 200k vs cur 20k - lol

    Sentiment: Strong Buy

CUR
2.03-0.150(-6.88%)Apr 17 4:00 PMEDT